

CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

215413Orig1s000

Trade Name: TRIUMEQ PD

Generic or Proper Name: abacavir, dolutegravir, lamivudine

Sponsor: ViiV Healthcare Company

Approval Date: March 30, 2022

Indication: TRIUMEQ PD is indicated for the treatment of HIV-1 infection in pediatric patients weighing at least 10 kg

CENTER FOR DRUG EVALUATION AND RESEARCH

215413Orig1s000

CONTENTS

Reviews / Information Included in this NDA Review.

Approval Letter	X
Other Action Letters	
Labeling	X
REMS	
Summary Review	
Officer/Employee List	X
Office Director Memo	
Cross Discipline Team Leader Review	X
Clinical Review(s)	X
Product Quality Review(s)	X
Non-Clinical Review(s)	
Statistical Review(s)	
Clinical Microbiology / Virology Review(s)	X
Clinical Pharmacology Review(s)	X
Other Reviews	X
Risk Assessment and Risk Mitigation Review(s)	
Proprietary Name Review(s)	X
Administrative/Correspondence Document(s)	X

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

215413Orig1s000

APPROVAL LETTER



NDA 215413

NDA APPROVAL

ViiV Healthcare Company
c/o GlaxoSmithKline
Attention: Stephen Hyatt
Manager, Global Regulatory Affairs
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709

Dear Mr. Hyatt:

Please refer to your new drug application (NDA) dated September 29, 2021, received September 30, 2021, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Triumeq PD (abacavir, dolutegravir, lamivudine) tablets for oral suspension.

This NDA provides for the following:

- The use of Triumeq PD (abacavir, dolutegravir, lamivudine) tablets for oral suspension for treatment of HIV-1 infection in pediatric patients weighing 10 to less than 25 kg
- A WARNING Card that should be carried by patients or care givers

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

WAIVER OF ½ PAGE LENGTH REQUIREMENT FOR HIGHLIGHTS

We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of Prescribing Information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at

FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information, Medication Guide, and Instructions for Use) as well as annual reportable changes not included in the enclosed labeling. Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

The SPL will be accessible via publicly available labeling repositories.

CARTON AND CONTAINER LABELING

Submit final printed carton and container labeling that are identical to the enclosed carton and container labeling as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*. For administrative purposes, designate this submission **“Final Printed Carton and Container Labeling for approved NDA 215413.”** Approval of this submission by FDA is not required before the labeling is used.

DATING PERIOD

Based on the stability data submitted to date, the expiry dating period for Triumeq PD (abacavir, dolutegravir, lamivudine) tablets for oral suspension shall be 36 months from the date of manufacture when stored at 20°C to 25°C (68°F to 77°F); excursion permitted between 15°C and 30°C (59°F to 86°F). [See USP Controlled Room Temperature].

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study requirement for ages 0 to less than 2 years because necessary studies are impossible or highly impracticable. This is because the number of these patients is too small.

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

We are deferring submission of your pediatric study in children who are at least 2 years of age and weighing at least 10 kg and up to 25 kg (e.g., ages 2 to less than 6 years of age) because this product is ready for approval for use in other patient populations and additional data are expected for pediatric patients weighing 10 to less than 25 kg.

Your deferred pediatric study required by section 505B(a) of the FDCA is a required postmarketing study. The status of this postmarketing study must be reported annually according to 21 CFR 314.81 and section 505B(a)(4)(C) of the FDCA. This required study is listed below.

- 4247-1 Conduct a pediatric trial to evaluate the pharmacokinetics (PK), safety, and antiviral activity (efficacy) of abacavir/dolutegravir/lamivudine FDC tablets for oral suspension in HIV-infected pediatric subjects 2 years to less than 6 years of age. The safety and antiviral activity (efficacy) of abacavir/dolutegravir/lamivudine FDC tablets for oral suspension in pediatric subjects should be evaluated for a minimum of 24 weeks.

Final Protocol Submission: 12/2017 (submitted)

Study Completion: 01/2022

Final Report Submission: 01/2023

FDA considers the term *final* to mean that the applicant has submitted a protocol, the FDA review team has sent comments to the applicant, and the protocol has been revised as needed to meet the goal of the study or clinical trial.³

Submit the protocol(s) to your IND 114820 with a cross-reference letter to this NDA. Reports of this required pediatric postmarketing study must be submitted as an NDA or as a supplement to your approved NDA with the proposed labeling changes you believe are warranted based on the data derived from this study. When submitting the reports, please clearly mark your submission "**SUBMISSION OF REQUIRED PEDIATRIC ASSESSMENTS**" in large font, bolded type at the beginning of the cover letter of the submission.

This product is appropriately labeled for use in pediatric patients 6 years of age and older and weighing at least 25 kg for this indication. Therefore, no additional studies are needed in this pediatric group.

We note that labeling is also inclusive of pediatric patients weighing at least 10 kg. However, additional data are expected under the PREA PMR listed above.

³ See the guidance for Industry *Postmarketing Studies and Clinical Trials—Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act* (October 2019).

<https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs.*⁴

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the Prescribing Information, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at FDA.gov.⁵ Information and Instructions for completing the form can be found at FDA.gov.⁶

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

Your product is a Part 3 combination product (21 CFR 3.2(e)); therefore, you must also comply with postmarketing safety reporting requirements for an approved combination product (21 CFR 4, Subpart B). Additional information on combination product postmarketing safety reporting is available at FDA.gov.⁷

⁴ For the most recent version of a guidance, check the FDA guidance web page at <https://www.fda.gov/media/128163/download>.

⁵ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

⁶ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

⁷ <https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products>

If you have any questions, call Kevin Allen, Regulatory Project Manager, at 301-837-7467 or 301-796-1500.

Sincerely,

{See appended electronic signature page}

Yodit Belew, MD
Deputy Director (Acting)
Division of Antivirals
Office of Infectious Diseases
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling
 - Prescribing Information
 - Medication Guide
 - Instructions for Use
- Carton and Container Labeling

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

YODIT BELEW
03/30/2022 02:22:53 PM